Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Exclusion Criteria

• •1. HCV infection of mixed GT (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening.
• •2. HCV infection of sub-GT1a, mixed GT1a/1b, or undefined GT1.
• •3. Liver disease due to causes other than chronic HCV infection.
• •4. HIV infection.
• •5. Hepatitis B virus infection based on presence of HBs-Ag.
• •6. Confirmed or suspected active malignancy or history of malignancy within the last 5 years prior to screening.
• •7. History of illicit drug abuse other than cannabis or chronic alcohol abuse within 12 months prior to randomisation.
• •8. Subject is not willing to comply with the precautionary measures to prevent photosensitivity (avoid excessive sun exposure and use sun block on a daily basis).
• •9. Decompensated liver disease, or history of decompensated liver disease.
• •10. Clinical evidence of unstable cardiovascular disease which may further decompensate due to anemia.
• •11. Red blood cell disorders.
• •12. Body weight \<40 kg or \>125 kg.